about
Apolipoprotein C-I binds free fatty acids and reduces their intracellular esterificationMacrophage-specific inhibition of NF-kappaB activation reduces foam-cell formationApolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivoSevere hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPLPlasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic miceEstimation of activity related energy expenditure and resting metabolic rate in freely moving mice from indirect calorimetry dataLipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP miceThe role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?Response of apolipoprotein E*3-Leiden transgenic mice to dietary fatty acids: combining liver proteomics with physiological data.ApoE plasma levels and risk of cardiovascular mortality in old agePrenatal exposure to apoE deficiency and postnatal hypercholesterolemia are associated with altered cell-specific lysine methyltransferase and histone methylation patterns in the vasculature.High levels of dietary stearate promote adiposity and deteriorate hepatic insulin sensitivity.Hepatocyte-specific IKKβ expression aggravates atherosclerosis development in APOE*3-Leiden miceAspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet.Inhibition of the central melanocortin system decreases brown adipose tissue activityThe expression of type III hyperlipoproteinemia: involvement of lipolysis genesGLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden miceAcute central neuropeptide Y administration increases food intake but does not affect hepatic very low-density lipoprotein (VLDL) production in miceZnf202 affects high density lipoprotein cholesterol levels and promotes hepatosteatosis in hyperlipidemic mice.Both transient and continuous corticosterone excess inhibit atherosclerotic plaque formation in APOE*3-leiden.CETP miceEstablishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology.Hepatocyte-specific IKK-β activation enhances VLDL-triglyceride production in APOE*3-Leiden miceAnacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.The effect of PPE-induced emphysema and chronic LPS-induced pulmonary inflammation on atherosclerosis development in APOE*3-LEIDEN mice.A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetesCETP expression reverses the reconstituted HDL-induced increase in VLDL.Circulating insulin stimulates fatty acid retention in white adipose tissue via KATP channel activation in the central nervous system only in insulin-sensitive mice.Stimulatory effect of insulin on glucose uptake by muscle involves the central nervous system in insulin-sensitive miceMetabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology.Apolipoproteins modulate the inflammatory response to lipopolysaccharide.ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiencyPreoperative apolipoprotein CI levels correlate positively with the proinflammatory response in patients experiencing endotoxemia following elective cardiac surgery.Gut-brain axis.Maternal transmission of risk for atherosclerosis.Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: studies using genetically engineered mouse models.Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.Sympathetic nervous system control of triglyceride metabolism: novel concepts derived from recent studies.CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice.Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis.Specific and efficient targeting of adenovirus vectors to macrophages: application of a fusion protein between an adenovirus-binding fragment and avidin, linked to a biotinylated oligonucleotide.
P50
Q24299172-1D36FAEB-ABE2-4960-AA37-14E6CE4C5566Q24300872-A66AE070-5563-409C-AC33-B67BF4D1102BQ24312753-89BBC4C2-F8DF-495C-87D8-B7F17A77D3B2Q24319030-544CDF01-A269-448B-88F9-C74B33C3675DQ27344569-0041FDDA-5381-4D68-9CA4-930FB6B687C0Q28730126-E940E215-9007-4A16-8CAE-BF57B0C27BDFQ28732458-AE6F4A94-278D-4444-BB82-353248F6CC96Q30341682-88C9E92F-75F6-49E6-B9D5-BD66D0ABBD3CQ30984423-6DA1F7F1-1DDE-46B5-BE2E-A60D3548F847Q33242076-73FF65CA-F703-4994-98B4-C0B0F80C06A9Q33597037-52EDE96D-DD2F-4530-BAE3-3024C9642D78Q33780322-1A59C7CA-5247-4567-991D-7DAE73013BD7Q33898304-8577A4DC-30B7-4142-84B3-F9B23087BD30Q33976115-FE8CDB91-DFD7-41F5-84C4-658D40F741DBQ34238637-C07106D7-6373-46C6-A52B-DC90682028C5Q34326186-1373A16A-DBBF-4A80-B78B-DF83F0757796Q34469947-E8F17C38-4319-46CF-BEA3-270E735D6DD2Q34608233-223C55E1-90F5-4E07-ABBB-729D626C06AFQ34612131-3758942D-0C6A-45D3-94E0-8B927951F9F5Q34744777-1E811172-4960-4FB7-BC88-84DD074500D1Q34764818-838E3D96-BDB6-40E6-A341-EBC9EE567DB4Q34776315-CF204B1C-6548-4300-A084-C35D0E8CA8A0Q34858025-0933F2F5-2DC9-4CB4-AA07-275BC8F6B906Q35058473-EB226D53-957B-4E3D-954D-22CBB658049BQ35094217-0BF28433-23A5-40E6-964B-29A0B34C0B0BQ35107299-B445C42E-0E05-423A-858B-A30366DF0722Q35152229-72865D7B-F33B-4D81-89C8-B0B82BAA96D2Q35561118-E2C89ED2-FEFC-4790-8E43-A0A173F8A8EFQ36149802-A9888ECD-AD81-40A4-97F8-E6B6D3927F04Q36159060-ACBC8C73-BC83-43B2-B7AE-D79D79ECC9E8Q36558367-BEFB8510-83E2-4861-96D9-7DE0028605EAQ36800299-655E2128-99D9-41C4-963F-C5EAA12F4758Q37187316-2E1CD026-0B01-44A7-990D-3113FE906C1AQ37209360-1CE0E180-E498-460C-B61F-086829E2FE48Q37377010-5C2D6CD4-F2A0-4CCC-8C15-BB48B8363D68Q37430584-95A3BAC5-F382-483E-A5C2-2AF7FEE2D8DAQ37457206-9DE0B3C0-A929-4FA9-91B4-22C41917D497Q37463344-10EC2687-72E8-434F-A1BE-C2F3B3AF5761Q38091828-8AC55CEB-58BB-4B70-B931-902FA54D68BEQ38315060-9B1E5790-6478-4684-99F3-FE3E30844DB6
P50
name
Louis M Havekes
@ast
Louis M Havekes
@en
Louis M Havekes
@nl
type
label
Louis M Havekes
@ast
Louis M Havekes
@en
Louis M Havekes
@nl
prefLabel
Louis M Havekes
@ast
Louis M Havekes
@en
Louis M Havekes
@nl